Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022

Rhea-AI Summary

Pulmonx Corporation (NASDAQ: LUNG) will announce its Q2 2022 financial results on August 2, 2022, after market close. A conference call will be held at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. Pulmonx is a leader in minimally invasive treatments for lung disease, notably through its FDA-approved Zephyr® Endobronchial Valve, which is available in over 25 countries. The company has treated more than 25,000 patients with over 100,000 valves used.

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Participants are required to register online, and should do so at minimum 15 minutes before the start of the call. Investors interested in listening to the conference call are requested to register online or view the live and archived webcast of the event available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit https://uspatients.pulmonx.com/. For more information on the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005181/en/

Brian Johnston

Gilmartin Group

investors@pulmonx.com

Source: Pulmonx Corporation

FAQ

When will Pulmonx Corporation release its Q2 2022 financial results?

Pulmonx Corporation will release its Q2 2022 financial results on August 2, 2022.

What time will the Pulmonx financial results conference call start?

The conference call will start at 1:30 p.m. PT (4:30 p.m. ET) on August 2, 2022.

How can I listen to the Pulmonx conference call?

You can listen to the conference call by registering online or viewing the live and archived webcast on the Pulmonx Investors website.

What is Pulmonx's main product?

Pulmonx's main product is the Zephyr® Endobronchial Valve, designed for treating severe emphysema/COPD.

In how many countries is the Zephyr Valve available?

The Zephyr Valve is commercially available in over 25 countries.